Frederick Lei
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Frederick Lei has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Alex Dahlen
Biostatistical Collaboration and Consultation Core (BC3), Department of Biostatistics, School of Global Public Health New York University New York New York USA
1 shared publication - Cheryl Healton
Department of Public Health Policy and Management, School of Global Public Health, New York University , New York, NY
1 shared publication - Christian E. Johnson
Office of National Drug Control Policy, Executive Office of the President , Washington, DC
1 shared publication - José Antonio Pagán
Affiliation School of Global Public Health, New York University, New York, New York, United States of America
1 shared publication - Julie Holm
Department of Public Health Policy and Management, School of Global Public Health, New York University , New York, NY
1 shared publication - Kofi Agyabeng
Biostatistical Collaboration and Consultation Core (BC3), Department of Biostatistics, School of Global Public Health, New York University , New York, NY
1 shared publication
Latest Publications
- 27 March 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (4)
Illicit drug supply, naloxone availability, and overdose mortality in the fentanyl era: a systematic review
Background: The overdose crisis is shaped by increasing synthetic opioids and expanding access to naloxone. We synthesized evidence on associations between illicit drug supply, naloxone availability/distribution, and overdose mortality. Methods: Following PRISMA, we searched 4 databases for studies between 2015 and 2025. Eligible studies examined associations of drug supply indicators or naloxone interventions, and overdose mortality. Data were extracted and synthesized narratively. Results: Forty-seven studies met inclusion criteria. Eighteen studies assessed drug supply changes and all but 2 found significant positive associations between increased fentanyl reports in drug seizures and overdose mortality. Drug seizure data were interpreted as indicators of supply trends or as enforcement disruptions. Thirty-one studies assessed naloxone availability. Thirteen studies reported naloxone access laws, take-home naloxone programs, and/or community interventions were associated with reductions in overdose deaths. Nine studies reported null effects, particularly during the COVID-19 pandemic. Conclusions: Fentanyl reports in drug seizures and drug potency are key drivers of overdose mortality. This review highlights variability in interpreting drug seizure data and the need for clearer conceptualization in future research. Naloxone interventions show promise but depend on consistent implementation and effective targeting of high-risk populations. Coordinated public health strategies are needed to monitor the drug market and strengthen overdose prevention.
- 27 March 2026
- Published by Oxford University Press (OUP) in Health Affairs Scholar
- Vol. 4 (4)
Illicit drug supply, naloxone availability, and overdose mortality in the fentanyl era: a systematic review
Background: The overdose crisis is shaped by increasing synthetic opioids and expanding access to naloxone. We synthesized evidence on associations between illicit drug supply, naloxone availability/distribution, and overdose mortality. Methods: Following PRISMA, we searched 4 databases for studies between 2015 and 2025. Eligible studies examined associations of drug supply indicators or naloxone interventions, and overdose mortality. Data were extracted and synthesized narratively. Results: Forty-seven studies met inclusion criteria. Eighteen studies assessed drug supply changes and all but 2 found significant positive associations between increased fentanyl reports in drug seizures and overdose mortality. Drug seizure data were interpreted as indicators of supply trends or as enforcement disruptions. Thirty-one studies assessed naloxone availability. Thirteen studies reported naloxone access laws, take-home naloxone programs, and/or community interventions were associated with reductions in overdose deaths. Nine studies reported null effects, particularly during the COVID-19 pandemic. Conclusions: Fentanyl reports in drug seizures and drug potency are key drivers of overdose mortality. This review highlights variability in interpreting drug seizure data and the need for clearer conceptualization in future research. Naloxone interventions show promise but depend on consistent implementation and effective targeting of high-risk populations. Coordinated public health strategies are needed to monitor the drug market and strengthen overdose prevention.